Importantly, the innovative IDH inhibitor ivosidenib, that has a wild-type inhibitor active in myeloid neoplasms, may also be an alternative to be tested in IBD-CRCs, where IDH is usually not mutated. Here, IDH1 is linked to myeloid neoplasm.